ATE252374T1 - Eingekapselte antikörper-produzierende zellen - Google Patents

Eingekapselte antikörper-produzierende zellen

Info

Publication number
ATE252374T1
ATE252374T1 AT97954822T AT97954822T ATE252374T1 AT E252374 T1 ATE252374 T1 AT E252374T1 AT 97954822 T AT97954822 T AT 97954822T AT 97954822 T AT97954822 T AT 97954822T AT E252374 T1 ATE252374 T1 AT E252374T1
Authority
AT
Austria
Prior art keywords
producing cells
antibody producing
encapsulated antibody
encapsulated
capsules
Prior art date
Application number
AT97954822T
Other languages
English (en)
Inventor
Marc Piechaczyk
Mireia Pelegrin
Cochereau
Mariana Marin
Aiguelongue L
Robert Saller
Brian Salmons
Original Assignee
Bavarian Nordic As
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As, Centre Nat Rech Scient filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of ATE252374T1 publication Critical patent/ATE252374T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT97954822T 1996-12-23 1997-12-18 Eingekapselte antikörper-produzierende zellen ATE252374T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK149796 1996-12-23
PCT/EP1997/007120 WO1998027966A2 (en) 1996-12-23 1997-12-18 Encapsulated cells producing antibodies

Publications (1)

Publication Number Publication Date
ATE252374T1 true ATE252374T1 (de) 2003-11-15

Family

ID=8105461

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97954822T ATE252374T1 (de) 1996-12-23 1997-12-18 Eingekapselte antikörper-produzierende zellen

Country Status (11)

Country Link
US (1) US6426088B1 (de)
EP (1) EP0948319B1 (de)
JP (2) JP4727768B2 (de)
AT (1) ATE252374T1 (de)
AU (1) AU6205998A (de)
DE (1) DE69725754T2 (de)
DK (1) DK0948319T3 (de)
ES (1) ES2208973T3 (de)
PT (1) PT948319E (de)
SI (1) SI0948319T1 (de)
WO (1) WO1998027966A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168339A1 (en) * 1997-01-20 2002-11-14 Marc Piechaczyk Biological material for treating a mammal by antibody gene transfer and pharmaceutical composition containing same
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US9452238B2 (en) * 2000-07-29 2016-09-27 Smith & Nephew LLP Tissue implant
US20040014704A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent induces tolerance
US20040014698A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
US20040016013A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent
US20040220085A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Compositions for nucleic acid delivery
US20040219099A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Method for the treatment of tumors
US20050208032A1 (en) * 2004-01-16 2005-09-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
DE102005011367B4 (de) * 2005-03-11 2010-12-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung von Cellulosesulfat mit verbesserten Eigenschaften
KR101902035B1 (ko) 2011-01-25 2018-09-27 오스트리아노바 싱가포르 피티이 리미티드 산성 분해로부터 미생물 세포의 보호
GB201408233D0 (en) 2014-05-09 2014-06-25 Austrianova Singapore Pte Ltd Use of polyanionic composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6025929A (ja) * 1983-07-20 1985-02-08 ザ・スト−ル・リサ−チ・アンド・デイベロツプメント・コ−ポレ−シヨン カプセル化細胞、その製造方法および用途
ATE76331T1 (de) 1987-02-25 1992-06-15 Hoechst Ag Mikroenkapsulierung von biologisch aktivem material.
US5427935A (en) 1987-07-24 1995-06-27 The Regents Of The University Of Michigan Hybrid membrane bead and process for encapsulating materials in semi-permeable hybrid membranes
US5116747A (en) * 1989-08-11 1992-05-26 University Of Waterloo Immobilization of biologically active material in capsules prepared from a water-soluble polymer and chitosan acetate
US5686113A (en) 1995-03-21 1997-11-11 Temple University Of The Commonwealth System Of Higher Education Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses
US5997900A (en) * 1996-04-17 1999-12-07 Wang; Taylor G. Encapsulation system for the immunoisolation of living cells

Also Published As

Publication number Publication date
WO1998027966A3 (en) 1998-11-12
EP0948319B1 (de) 2003-10-22
US6426088B1 (en) 2002-07-30
JP2009013182A (ja) 2009-01-22
DE69725754T2 (de) 2004-08-19
EP0948319A2 (de) 1999-10-13
JP4727768B2 (ja) 2011-07-20
WO1998027966A2 (en) 1998-07-02
DK0948319T3 (da) 2004-02-09
AU6205998A (en) 1998-07-17
ES2208973T3 (es) 2004-06-16
PT948319E (pt) 2004-02-27
JP2001507344A (ja) 2001-06-05
DE69725754D1 (de) 2003-11-27
SI0948319T1 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
NO962088D0 (no) Preparat for in vivo-produksjon av terapeutiske produkter
EP1194164B8 (de) Prion protein peptide und deren verwendung
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
MXPA05013564A (es) Proteinas de fusion.
WO1997008318A3 (en) Compounds and methods for treatment and diagnosis of prostate cancer
WO1997019111A3 (es) Anticuerpos monoclonales anti-cd6 y sus utilizaciones
HUP0002831A3 (en) Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
ATE252374T1 (de) Eingekapselte antikörper-produzierende zellen
ATE229815T1 (de) In vitro methoden und verwendung von pharmazeutische zusammensetzungen für die behandlung von innenohrhaarzellen
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
WO2002072636A3 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
MXPA02000119A (es) Elementos mezcladores estaticos apilados.
DE60135498D1 (de) Produktion von ganzen Antikörpern in prokaryontischen Zellen
IL138424A (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
TR200102493T2 (tr) IgE'nin C-epsilon-3 veya C-epsilon-4 alanlarından türetilmiş epitoplar veya mimotoplar.
IL161832A0 (en) Pharmaceutical composition for inducing an immune response in a human or animal
WO1995019435A3 (en) T cell antigen receptor v region proteins and methods of preparation thereof
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
ATE234636T1 (de) Konjugat, umfassend einen wirkstoff, ein polypeptid und einen polyether
EP1801123A3 (de) Kristalle von ganzen Antikörpern und Fragmenten davon und Verfahren zu ihrer Herstellung und Verwendung
TR200100637T2 (tr) Yeni doğal ürün türevleri
TR200401775T4 (tr) 3-Amino-1-Fenil-1H[1,2,4] triazol'ün dallanmış değiştirilmiş yeni amino türevleri, bunların imali için metot ve bunları içeren farmosötik (eczacılık) bileşimleri
IT8967049A0 (it) Anticorpo umano monoclonale composizione terapeutica che lo contiene linea cellulare capace di produrre l anticorpo procedimento per la suaproduzione

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0948319

Country of ref document: EP